Compare Adaptive Biotechnologies Corp (ADPT) vs CleanSpark Inc (CLSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs CleanSpark Inc — how do they compare? Adaptive Biotechnologies Corp trades at $24.93 (market cap $4.04B), while CleanSpark Inc trades at $12.23 (market cap $2.96B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, CleanSpark Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | CLSK | |
|---|---|---|
Market Cap | $4.04B | $2.96B |
Sector | Health | Technology |
52-Week High | $25.45 | $23.20 |
52-Week Low | $12.30 | $8.18 |
Enterprise Value | $4.10B | $3.95B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
CleanSpark (CLSK) trades at $12.08, up 4.23% today but facing bearish technical signals with recent earnings misses. The company reported a Q3 2026 loss of $0.89 per share versus expectations of -$0.47, continuing a trend of negative profitability despite securing a significant $6.6 billion AI data center lease. Analyst sentiment remains strongly bullish with 11 buy ratings and a $24.13 consensus price target, representing 100% upside potential from current levels.
The stock presents a high-risk, high-reward opportunity with strong institutional support but significant execution challenges. While the AI infrastructure pivot offers long-term growth potential, near-term profitability concerns and negative cash flow create substantial volatility. Investors must weigh the disconnect between bullish analyst coverage and persistent earnings underperformance against the company's strategic repositioning in digital infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About CleanSpark Inc
CleanSpark is a leading Bitcoin mining company that operates high-density data centers. It focuses on using sustainable energy to power its mining fleet and provides digital infrastructure for the blockchain ecosystem.
Read more on CLSK →
